Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Richard J. Gralla(Jacobi Medical Center), A Depierre(National Cancer Centre Japan), Stephen Lane(Novartis (United States)), Joan H. Schiller(Virginia Department of Health), Nick G. Chrysson(National Cancer Centre Japan), Frances A. Shepherd(University Health Network), David J. Stewart(University of Ottawa), Peter Clark(National Cancer Centre Japan), Graham Ross(National Cancer Centre Japan), James Carmichael(AstraZeneca (United Kingdom)), Martin Palmer(National Cancer Centre Japan), Jacqueline B. Krebs(National Cancer Centre Japan), Scott Z. Fields(National Cancer Centre Japan), J P Kleisbauer(National Cancer Centre Japan)
Cited by 960
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k